ALK5抑制剂的设计、合成及其生物学活性评价
Design, synthesis and biological evaluation of ALK5 inhibitors
-
摘要: 以ALK5抑制剂LY-3200882作为先导化合物，利用生物电子等排和构象限制等药物设计策略，结合分子对接技术，设计并合成了10个结构新颖的化合物，其结构经1H NMR、HR-MS表征。体外活性筛选结果显示，大多数化合物具有良好的激酶抑制活性。其中，化合物B4表现出显著优于LY-3200882的ALK5抑制活性(IC50 = 1.4 nmol/L vs 41.1 nmol/L)，同时对NIH3T3细胞中TGFβ-ALK5-SMAD2/3信号通路具有良好的抑制活性(IC50 = 14.2 nmol/L)。进一步研究表明，化合物B4的药代动力学性质良好，口服暴露量及生物利用度满足成药性要求，值得进一步开发。
-
关键词:
- LY-3200882 /
- ALK5抑制剂 /
- 设计 /
- 合成 /
- 生物活性
Abstract: Using ALK5 inhibitor LY-3200882 as a lead compound, ten structurally novel compounds were designed by bioisosterism, conformational restriction and molecular docking technology. All structures were synthesized and confirmed by 1H NMR and HR-MS. The results of in vitro activity screening showed that most compounds had good kinase inhibitory activity. Among them, compound B4 showed significantly better ALK5 inhibitory activity than LY-3200882 (IC50 = 1.4 nmol/L vs 41.1 nmol/L), and had good inhibitory activity against TGFβ-ALK5-SMAD2/3 signaling pathway in NIH3T3 cells (IC50 = 14.2 nmol/L). Besides, compound B4 had good pharmacokinetic properties, such as oral exposure and bioavailability, which is worthy of further development.-
Keywords:
- LY-3200882 /
- ALK5 inhibitors /
- design /
- synthesis /
- biological activity
-
-
[1] Morikawa M，Derynck R, Miyazono K. TGF-β and the TGF-β family: context-dependent roles in cell and tissue physiology[J]. Cold Spring Harb Perspect Biol, 2016, 8(5): a021873 .[2] Horbelt D, Denkis A, Knaus P. A portrait of transforming growth factor β superfamily signalling: background matters[J]. Int J Biochem Cell Biol, 2012, 44(3):469-474. [3] Xiaoling T, Wencai G, Lingyun Z, et al. Physical interaction of STAT1 isoforms with TGF-β receptors leads to functional crosstalk between two signaling pathways in epithelial ovarian cancer[J]. J Exp Clin Canc Res, 2018, 37(1):103. [4] Heldin CH, Moustakas A. Signaling receptors for TGF-β family members[J]. Cold Spring Harb Perspect Biol, 2016, 8(8): a022053 .[5] Padua D, MassaguéJoan. Roles of TGFβ in metastasis[J]. Cell Res, 2016, 19(1):89-102. [6] Pickup M, Novitskiy S, Moses HL. The roles of TGFβ in the tumour microenvironment[J]. Nat Rev Cancer, 2013, 13(11):788-799. [7] Batlle E, Massague J. Transforming growth factor-beta signaling in immunity and cancer[J]. Immunity, 2019, 50(4):924-940. [8] Pei H, Parthasarathy S, Joseph S, et al. LY3200882, a novel, highly selective TGFβRI small molecule inhibitor[J]. Cancer Res, 2017, 77:955. [9] Goldberg FW , Ward RA , Powell SJ , et al. Rapid generation of a high quality lead for transforming growth factor-β (TGF-β) type I receptor (ALK5)[J]. J Med Chem, 2009, 52(23):7901-7905.
计量
- 文章访问数: 234
- HTML全文浏览量: 6
- PDF下载量: 554
下载:
